Postoperative Nausea and Vomiting
Conditions
Keywords
PONV, digestive signs and symptoms, vomiting, antiemetics, nausea, ramosetron
Brief summary
Ramosetron is effective in preventing postoperative nausea and vomiting. Several studies reported that ramosetron is also effective treatment of irritable bowel syndrome. The investigators examine the effect of ramosetron on postoperative bowel motility.
Detailed description
Ramosetron, a new potent and long-acting selective 5-HT3(5-hydroxytryptamine3) receptor anatagonist, is effective for preventing postoperative nausea and vomiting. Also several studies reported that ramosetron is effective treatment of diarrhea-predominant irritable bowel syndrome because it inhibits the accelerated colonic transit, abnormal colonic water transport, defecation abnormality, and the lowered colonic perceptual threshold by corticotrophin-releasing hormone, There is no study about the effect of ramosetron used for preventing postoperative nausea and vomiting on postoperative bowel motility. In this study, the investigators examine the effect of ramosetron on postoperative bowel motility.
Interventions
DRUGRamosetron
Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
DRUGNormal saline
Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
Sponsors
Kyunghee University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 20-70 yrs of age * ASA(American Society of Anesthesiologists) physical status class I or II * Scheduled for gynecological laparoscopic surgery
Exclusion criteria
* Allergic to study drugs * Antiemetics or steroids use within 24 hrs prior to surgery * Dependence upon opioids * Insulin dependent Diabetes Mellitus * Cardiovascular or pulmonary disease * Renal or hepatic insufficiency * BMI\>=35kg/m2 * History of motion sickness or PONV * Cigarette smoker * Conversion to open laparotomy from laparoscopic surgery * Pregnants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time from surgery to the passage of first flatus | Within 10 days after surgery |
Secondary
| Measure | Time frame |
|---|---|
| Time to first defecation | Within 10 days after surgery |
| Incidence of postoperative ileus | Within 10 days after surgery |
Other
| Measure | Time frame |
|---|---|
| Incidence and severity of postoperative nausea | 0-6 hours, 6-24 hours, and 24-48 hours after surgery |
| Incidence and severity of postoperative vomiting | 0-6 hours, 6-24 hours, and 24-48 hours after surgery |
Countries
South Korea
Contacts
Primary ContactYoungsoon Kim, M.D., Ph.D.
Outcome results
None listed